Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158282 | PMC |
| http://dx.doi.org/10.1080/0886022X.2021.1925297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimising Pirfenidone Dosage Regimens in Idiopathic Pulmonary Fibrosis: Toward a Guide for Personalised Treatment.
Xenobiotica
January 2025
Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic respiratory disorder for which pirfenidone is the recommended first-line anti-fibrotic treatment. While pirfenidone has demonstrated efficacy in slowing the progression of IPF, its use is associated with several challenges and unresolved issues that impact patient outcomes. Pirfenidone administration can result in gastrointestinal side effects, photosensitivity reactions, and significant drug interactions, particularly in patients with hepatic impairment.
View Article and Find Full Text PDF[Evaluation of the efficacy of antifibrotic drugs on cell cultures in Salzmann's nodular degeneration].
Vestn Oftalmol
December 2024
Krasnov Research Institute of Eye Diseases, Moscow, Russia.
Unlabelled: Excessive production of extracellular matrix is a key component in the pathogenesis of Salzmann's nodular degeneration (SND). studies of drugs that suppress excessive fibroblast activity may become crucial in developing pathogenetically oriented treatments for SND.
Purpose: This study evaluates the antifibrotic properties of pirfenidone and cyclosporine A (CsA) on cell cultures obtained from patients with SND.
Effect of Transforming Growth Factor-β Inhibition on Ureteral and Renal Scarring in a Rat Model of Upper Urinary Tract Ablation with Irreversible Electroporation.
Bioelectricity
December 2024
Department of Mechanical and Industrial Engineering, University of Massachusetts Amherst, Amherst, Massachusetts, USA.
Objective: To determine whether adjuvant transforming growth factor-β (TGF-β) inhibition with pirfenidone (PFD) can mitigate ureteral wall scarring and related complications in a rat model of upper urinary tract ablation with irreversible electroporation (IRE).
Methods: Transmural ablation of the ureter was performed with IRE in 24 rats. Post-IRE, animals were randomly assigned to receive PFD or no drug, followed by euthanasia at 2-, 5-, or 10-days.
Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer.
Int J Pharm
December 2024
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710; Department of Chemistry and Biochemistry, North Carolina Central University, Durham, NC 27707. Electronic address:
Article Synopsis
- The study focuses on an innovative thermosensitive quadpolymer designed for injection to deliver anti-fibrotic drugs, specifically targeting uterine fibroids while potentially preserving fertility.
- The quadpolymer functions as an injectable solution at room temperature and transforms into a stable gel at body temperature, allowing for sustained release of the drug pirfenidone.
- Results showed that the pirfenidone-loaded quadpolymer effectively inhibited fibroid cell proliferation, indicating its potential as a localized treatment option for uterine fibroid therapy.
Real-World Clinical Effectiveness and Safety of Antifibrotics in Progressive Pulmonary Fibrosis Associated with Rheumatoid Arthritis.
J Clin Med
November 2024
Interstitial Lung Disease Unit, Department of Pneumology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), 08907 Barcelona, Spain.
: Interstitial lung disease (ILD) is one of the most severe complications of rheumatoid arthritis (RA). Real-world data on antifibrotic treatment are needed. Our objective was to evaluate the real-world effectiveness and tolerability of antifibrotic agents in patients with progressive fibrosing RA-ILD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!